24小时热门版块排行榜    

CyRhmU.jpeg
查看: 1260  |  回复: 10
当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖

PSA

专家顾问 (著名写手)

[交流] NDA for tasocitinib to treat RA已有5人参与

Pfizer Inc. (NYSEFE), New York, N.Y.
Product: Tofacitinib (CP-690,550) (formerly tasocitinib)
Business: Autoimmune
Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1)
Description: Oral pan-Janus kinase (JAK) inhibitor
An NDA for tofacitinib to treat rheumatoid arthritis (RA) is
under FDA review with an Aug. 21 PDUFA date, while an MAA is
under review in the EU. The product is also under review in Japan.
In a conference call to discuss its 2Q12 earnings, Pfizer said FDA
requested additional analysis of data in the NDA for tofacitinib,
which the pharma said could cause the agency to extend its review
of the product past its PDUFA date. Specifics about the request
were not disclosed (see BioCentury, Aug. 6). Tofacitinib also is in
Phase III testing to treat moderate to severe plaque psoriasis.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has
rights from Pfizer to co-market tofacitinib in Japan for RA and other
undisclosed indications
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

meadows

铜虫 (小有名气)


小木虫: 金币+0.5, 给个红包,谢谢回帖
国外寄予厚望的一个药,主要就是新靶点和口服给药吧,fda批了吗,貌似化合物专利2020年后了,仿制有点早
11楼2013-02-20 21:45:48
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 11 个回答

cpujacs

荣誉版主 (知名作家)

优秀版主优秀版主优秀版主



小木虫: 金币+0.5, 给个红包,谢谢回帖
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market tofacitinib in Japan for RA and other undisclosed indications
这种合作是不是将来的一种趋势
3楼2012-08-20 13:15:10
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

PSA

专家顾问 (著名写手)

合作开发,挺好的呵呵!
4楼2012-08-20 13:22:26
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

PSA

专家顾问 (著名写手)

引用回帖:
5楼: Originally posted by 药道人 at 2012-08-20 14:29:39
不看好

你不看好tofacitinib上市?还是不看好合作开发呵呵!
6楼2012-08-20 15:29:08
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
普通表情 高级回复(可上传附件)
信息提示
请填处理意见